23 Jul, 2026
According to Straits Research, the global ophthalmic drugs market valued at $40.93 billion in 2025, is projected to grow from $44.23 billion in 2026 to $84.64 billion by 2034 at a CAGR of 8.45% during the forecast period 2026–2034.
Anti-infectives in a product designed specifically to be injected into or applied to the eye or eyes are known as ophthalmic anti-infectives. An example of an anti-infective for the eyes is eyedrops, gels, and ointments. Anti-infective medications either eliminate or stop the spread of an infectious pathogen. The demand is likely to increase due to increased research and development activities to create and release novel ophthalmic drugs and various strategic initiatives that the key players anticipate.
The global market for ophthalmic medicines is expected to expand successfully as more and more industry players place an increasing emphasis on R&D to develop cutting-edge therapies. Market players are extensively spending R&D to treat eye disorders with novel drugs and grow their market share. Many people strive to develop novel therapies because it is well known that current treatments for many illnesses, including dry eye and glaucoma, only provide temporary symptomatic alleviation.
The product's multiyear drug delivery system gives it a significant edge over competitors. Developing gene therapies as effective drug delivery is one of the major factors driving this industry. Gene therapy enables the modification of patient cells to produce particular therapeutic entities using viral or non-viral vectors in both in vitro and in vivo settings. Gene therapy can identify and treat retinoblastoma, neurovascular retinal abnormalities, and inherited ophthalmic illnesses like retinitis pigmentosa. More study is still needed to advance and expand the application of gene therapy for ocular illnesses, which is expected to create opportunities for market growth over the forecast period.
North America dominated the ophthalmic drugs market in 2025, accounting for 43.07% market share. This dominance is attributed to strong adoption of advanced ophthalmic therapies, favorable reimbursement policies, an increase in screening programs, and active research and development initiatives by leading pharmaceutical companies such as AbbVie, Pfizer, Alcon, and others.
Asis Pacific is emerging as a fastest-growing region with a CAGR of 10.11% from 2026-2034, owing to the rising prevalence of eye disorders, increasing geriatric population, growing healthcare expenditure, improving access to advanced ophthalmic treatments, and expanding awareness about eye care. Moreover, countries such as China and South Korea are actively developing domestic biologics, which also supports the market growth.
sales@straitsresearch.com